ARMY MEDICAL RESEARCH DEVELOPMENT CENTER MEMO

File: 970101_sep96_decls58_0002.txt
Page: 0002
Total Pages: 2

Subject: ARMY MEDICAL RESEARCH DEVELOPMENT CENTER MEMO                   

Unit: OTSG        

Parent Organization: HSC         

Box  ID: BX003205

Folder Title: TREATING LEISHMANIASIS WITH KETOCONAZOLE-PLACEBO AND PENTOSTAM                                  

Document Number:          1

Folder Seq  #:          6








               SGRE).Uwz-p                                  19 Dec 90
                      t

               MEMORANDUM FOR Director Professional Services, OTSGI BG R. Slanck

               SUBJPCT: Operation Desert Shield and Leishmaniasis


               1. Col C. Pederson, Commander USAMMDA, has requested the memorandum of the USAMROC
               Leishmaniasis Steering Committee, with respect to Leishmantasis In Operation Desert Shield, be
               sent to:you at this time that leishmaniasis Is apparently being seen in the Persian Gulf region.

               2. The memorandum Is appended.

               3. The summarized recommendations are:
                    a. bjagnosis: Medical assets In the Persian-Gulf Region be trained by USAMRDC in tne
               paras@ologloat diagnosis of leishmanlasis by aspiration and Vopsy. it only clinical diagnosis is
               available, some patients who do not In fact have lelshmaniasls will be treated with potentially
               toxic drugs.

                    b. Treatment:

                        'Cutaneous disease: All patients with cutaneous disease be randomized between
               ketoconazole (600 mg once a day for 28 days: In Theater) and plac@ (vitamin treatment) in a
               study situation, or be given katoconazole In a treatment situation. Pentostam treatment of
               cutaneous disease (20 mg/kg/day for 20 days: In Theater) be reserved for sporatic cases or for
               patients who fall ketoconazole. Because the optimum use of Pentastam (and ketooonazole)
               requires knowledge only available at USAMROC via IO years of clinical investigation, medical
               corps personnel In the Persian Gulf region should be made associate Investigators of the
               USAMROO Pentostam protocol and receive appropriate training.


                        Visceral disease,. All cases of visceral disease be given Pentostam (20 mgikg/day for 30
 this purpose.
                        hota-. Good treatment records should be centrally reposited at LISAMRDC so that the
               experience of Operation Desert Shield can guide future treatment of DoD foces.

               41  POC:  Tel: 202-576-3453      FAX: 202-576-3114



                                                         /JONATHAN BERMAN
                                                            00L. Mc
                                                            Chairman, MROO Leishmerilasis Steering Committee

Document 2 f:/Week-36/BX003205/TREATING LEISHMANIASIS WITH KETOCONAZOLE-PLACEBO AND PENTOSTAM/army medical research development center memo:12249609314259
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003205
Unit = OTSG
Parent Organization = HSC
Folder Title = TREATING LEISHMANIASIS WITH KETOCONAZOLE-PLACEBO AND PENTOSTAM
Folder Seq # = 6
Subject = ARMY MEDICAL RESEARCH DEVELOPMENT CENTER MEMO
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 24-DEC-1996